Jay Nelson, director of the OHSU Vaccine & Gene Therapy Institute, has been awarded a $10 million contract from the National Institutes of Health for discovery work on new ways to improve vaccines. They were one of seven groups awarded such contracts. Vaccine adjuvants are compounds that bolster the innate immune response, essentially super-charging the vaccine. While adjuvants show great promise in improving vaccines and fighting disease, currently just three are in use–scientists at VGTI and other institutions will begin to screen millions of molecules in search of more. Read the NIH press release here.